Last reviewed · How we verify

NCT01136720

Clinical Trial to Evaluate the Safety and Clinical Utility of 18F-FDG Produced by the Molecular Imaging and Research Centre of Nova Scotia

Completed Last updated 21 August 2024
What this trial tests

trial in 18FDG in 9,463 participants. Completed in 18 April 2017.

Timeline
19 June 2010
Primary endpoint
18 April 2017
18 April 2017

Quick facts

Lead sponsorNova Scotia Health Authority
StatusCompleted
Study typeOBSERVATIONAL
Enrollment9,463
Start date19 June 2010
Primary completion18 April 2017
Estimated completion18 April 2017
Sites1 location across Canada

Conditions studied

Sponsor

Nova Scotia Health Authority — full company profile →

Who can join

1 and older, any sex, with 18FDG. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

18F-FDG produced in the MIRC NS has a similar safety profile to the same compound utilized elsewhere in that no significant adverse events will occur during observation of the patients for 2 1/2 hours post injection of the tracer. It is also hypothesized that as this FDG produced by similar methodology and its quality assurance assessed as in another jurisdictions will have similar performance parameters in patients with focal lung pathology to that previously determined.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Nova Scotia Health Authority trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01136720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing